Compare Gilead Sciences, Inc. (GILD) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs BlackRock TCP Capital Corp — how do they compare? Gilead Sciences, Inc. trades at $136.45 (market cap $163.51B), while BlackRock TCP Capital Corp trades at $3.34 (market cap $276.88M). The key difference: Gilead Sciences, Inc. is far larger — about 590.5× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays the higher dividend (25.45%). Which is the better fit depends on your goals.
| GILD | TCPC | |
|---|---|---|
Market Cap | $163.51B | $276.88M |
Sector | Health | Financials |
52-Week High | $155.80 | $7.84 |
52-Week Low | $108.22 | $3.14 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | 25.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
BlackRock TCP Capital Corp. (TCPC) trades at $3.32, up 5.06% on the day, against a backdrop of mixed technical and fundamental signals. The stock is technically bearish with key moving averages signaling caution, while fundamental metrics show a challenging picture with negative revenue and net income, though a low P/B ratio of 0.49 suggests potential undervaluation. Recent news includes a Zacks upgrade to 'Buy' and an upcoming Q2 2026 earnings report on August 6, 2026.
The outlook for TCPC is clouded by persistent negative profitability and a shareholder lawsuit investigation, presenting significant risk. However, a discounted book value, a stable dividend, and a recent analyst upgrade offer a potential value opportunity for income-focused investors willing to tolerate high volatility and fundamental uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
